Show simple item record

dc.contributor.authorPlummer, R
dc.contributor.authorCook, Natalie
dc.contributor.authorArkenau, T
dc.contributor.authorMelear, J
dc.contributor.authorRedfern, C
dc.contributor.authorSpira, A
dc.contributor.authorChung, K
dc.contributor.authorHaddad, T
dc.contributor.authorRamalingam, S
dc.contributor.authorWesolowski, R
dc.contributor.authorDean, Emma J
dc.contributor.authorGoddemeier, T
dc.contributor.authorFalk, M
dc.contributor.authorShapiro, G
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationPlummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI, et al. 1437P Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8):519.en
dc.identifier.doi10.1093/annonc/mdy292.059en
dc.identifier.urihttp://hdl.handle.net/10541/621813
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy292.059en
dc.titlePhase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNorthern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T12:02:11Z


Files in this item

Thumbnail
Name:
561665.pdf
Size:
91.35Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record